A California drug company has agreed to pay more than $95 million to settle two whistleblower complaints claiming it paid kickbacks to physicians and marketed the drug Nuedexta for off-label uses that resulted in millions of dollars in fraudulent medical claims, the U.S. Justice Department announced Thursday.

The whistleblower complaint against Avanir Pharmaceuticals—unsealed Monday in the U.S. District Court for the Northern District of Georgia—alleges that company sales representatives aggressively marketed Nuedexta to nursing homes and assisted living facilities for use in narcotizing patients for behaviors commonly associated with dementia, even though the drug was only approved for treating a rare neurological condition known as pseudobulbar affect. The condition is characterized by uncontrollable crying or laughter.